ВОРАПАКСАР - ПЕРВЫЙ ПРЕДСТАВИТЕЛЬ НОВОГО КЛАССА АНТИАГРЕГАНТОВ
- Авторы: Ушкалова Е.А1
-
Учреждения:
- РУДН
- Выпуск: № 9 (2014)
- Страницы: 76-80
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/286978
- ID: 286978
Цитировать
Полный текст
Открытый доступ
Доступ предоставлен
Доступ платный или только для подписчиков
Аннотация
Ключевая роль в патогенезе атеротромбоза принадлежит тромбоцитам, поэтому основной фармакологической группой, применяемой для первичной и вторичной профилактики атеротромботических осложнений, являются антиагреганты. Предложен обзор исследований ворапаксара - первого представителя нового класса антиагрегантов - антагонистов активируемых протеазой рецепторов (PAR-1) тромбина.
Ключевые слова
Полный текст
Об авторах
Е. А Ушкалова
РУДН
Email: eushk@yandex.ru
д.м.н., проф. кафедры общей и клинической фармакологии
Список литературы
- Silva M.V., Dusse L.M., Vieira L.M., Carvalho M.D. Platelet antiaggregants in primary and secondary prevention of atherothrombotic events. Arq Bras Cardiol. 2013; 100(6): e78-84.
- Люсов В.А., Таратухин Е.О. Перспективы антитромбоцитарной терапии. Российский кардиологический журнал. 2011; 1: 65-70.
- Food and Drug Administration. FDA approves Zontivity to reduce the risk of heart attacks and stroke in high-risk patients [press release]. May 8, 2014.
- Abdulsattar Y., Ternas T., Garcia D. Vorapaxar: targeting a novel antiplatelet pathway. 2011; 36(9): 564-68.
- Martorell L., Martinez-Gonzalez J., Rodriguez C., et al. Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb Haemost. 2008; 99(2): 305-15.
- Coughlin S.R. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost. 2005; 3(8): 1800-14.
- Goto S., Yamaguchi T., Ikeda Y., et al. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J. Atheroscler Thromb. 2010; 17: 156-64.
- Chackalamannil S., Wang Y., Greenlee W.J., et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent anti-platelet activity. J. Med. Chem. 2008; 51: 3061-64.
- Ueno M., Ferreiro J.L., Angiolillo D.J. Mechanism of action and clinical development of platelet thrombin receptor antagonists. Expert Rev. Cardiovasc. Ther. 2010; 8(8): 1191-200.
- Xia Y., Chackalamannil S., Greenlee W.J., et al. Discovery of a vorapaxar analog with increased aqueous solubility. Bioorg. Med. Chem. Lett. 2010; 20(22): 6676-79.
- Merck & Co., Inc. (MRK) Release: FDA Approves ZONTIVITY™ (Vorapaxar), First-In-Class PAR-1 Antagonist, For The Reduction Of Thrombotic Cardiovascular Events In Patients With A History Of Heart Attack Or With Peripheral Arterial Disease. http://www.biospace.com/news_story.aspx?StoryID=333184.
- Kosoglou T., Reyderman L., Tiessen R., et al. TRAP-induced platelet aggregation following single and multiple rising doses of SCH 530348, a novel thrombin receptor antagonist, in healthy volunteers. Pharmacol. Ther. 2009; 85(Suppl 1): S21.
- Kosoglou T., Reyderman L., Tiessen R.G., et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur. J. Clin. Pharmacol. 2012; 68(3): 249-58.
- Kosoglou T., Reyderman L., Kasserra C., et al. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. Eur. J. Clin. Pharmacol. 2012; 68(3): 291-300.
- Becker R.C., Moliterno D.J., Jennings L.K., et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomized, double-blind, placebo-controlled phase II study. Lancet. 2009; 373(9667): 919-28.
- Morrow D.A., Braunwald E., Bonaca M.P., et al. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 2012; 366(15): 1404-13.
- Cho J.R., Rollini F., Franchi F., Ferrante E., Angiolillo D.J. Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar. Vasc Health Risk Manag. 2014; 10: 177-188.
- TRA 2P-TIMI 50: Future Possible for Vorapaxar in Patients With Prior MI. Medscape. Mar 24, 2012.
- Bonaca M.P., Scirica B.M., Creager M.A., et al. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation. 2013; 127(14): 1522-29, 1529e1-6.
- Tricoci P., Huang Z., Held C., et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N. Engl. J. Med. 2012; 366(1): 20-3.
- Финансовые показатели «Merck & Co» за 2010 год http://www.remedium.ru/news
- Food and Drug Administration. FDA approves Zontivity to reduce the risk of heart attacks and stroke in high-risk patients [press release]. May 8, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm396585.htm
Дополнительные файлы
